Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyColorado Rocky Mountain Health Plans Oxlumo Rivflo…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy CSOH2026D0102.F

    Oxlumo (lumasiran) and Rivfloza (nedosiran) — Coverage Criteria (Ohio)

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CSOH2026D0102.F alerts

    Get alerted when Policy CSOH2026D0102.F changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit drug coverage criteria for Oxlumo and Rivfloza for treatment of primary hyperoxaluria type 1 (PH1); applies to requests evaluated under Ohio jurisdiction per the policy.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyOxlumo (lumasiran) and Rivfloza (nedosiran) — Coverage Criteria (Ohio)
    Policy CodePolicy CSOH2026D0102.F
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with medical records documenting PH1 diagnosis confirmation and, for continuation, evidence of positive clinical response versus pretreatment baseline.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsauthorization period
    eGFR ≥ 30Rivfloza kidney function
    age ≥ 2Rivfloza age minimum
    PH1 requireddiagnosis

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0224/J3490/C9399listed drug codes

    Coverage Criteria for Oxlumo and Rivfloza

    Initial Therapy — Oxlumo (lumasiran)

    Oxlumo (lumasiran) is covered when ALL of the following are met for initial therapy:

    Oxlumo initial therapy criteria: Diagnosis of PH1 by, or in consultation with, a specialist (e.g., geneticist, nephrologist, urologist) with expertise in PH1; confirmation of PH1 diagnosis by metabolic testing demonstrating either increased urinary oxalate excretion (e.g., >1 mmol/1.73 m2/day or increased urinary oxalate:creatinine ratio relative to age norms) or increased plasma oxalate and glyoxylate concentrations; submission of medical records documenting a positive clinical response to therapy from pretreatment baseline (e.g., decreased urinary oxalate concentrations, decreased urinary oxalate:creatinine ratio, decreased plasma oxalate concentrations); patient has not received a liver transplant; patient is not receiving Oxlumo in combination with Rivfloza (nedosiran); prescribed by, or in consultation with, a specialist experienced in PH1; dosing per FDA-approved labeling; initial/reauthorization period limited to no more than 12 months.

    Documentation of baseline and on-treatment laboratory values should be submitted as medical records to support response assessment.

    Initial and Continuation Therapy — Rivfloza (nedosiran)

    Rivfloza (nedosiran) is covered when ALL of the following are met for initial therapy:

    Rivfloza initial therapy criteria: Genetic testing confirming a pathogenic mutation in AGXT (AGT); patient has not received a liver transplant; patient is ≥ 2 years of age; patient has relatively preserved kidney function (e.g., eGFR ≥ 30 mL/min/1.73 m2); patient is not receiving Rivfloza in combination with Oxlumo (lumasiran); prescribed by, or in consultation with, a specialist experienced in PH1; dosing per FDA-approved labeling; initial authorization limited to no more than 12 months.eGFR ≥ 30 mL/min/1.73 m2

    Age and kidney function thresholds reflect FDA-labeled indication and policy requirements.

    Rivfloza continuation criteria: Submission of medical records documenting a positive clinical response from pretreatment baseline (e.g., decreased urinary oxalate concentrations, decreased urinary oxalate:creatinine ratio, decreased plasma oxalate concentrations); patient has not received a liver transplant; patient maintains relatively preserved kidney function (eGFR ≥ 30 mL/min/1.73 m2); patient is not receiving combination therapy with Oxlumo (lumasiran); prescribed by, or in consultation with, a specialist experienced in PH1; dosing per FDA-approved labeling; reauthorization limited to no more than 12 months.eGFR ≥ 30 mL/min/1.73 m2

    Provide laboratory documentation comparing on-treatment values to pre-treatment baseline to support continued benefit.

    Use of Oxlumo (lumasiran) and Rivfloza (nedosiran) together is not permitted. The policy explicitly states that a patient must not be receiving Oxlumo in combination with Rivfloza (and conversely must not be receiving Rivfloza in combination with Oxlumo) as a condition of coverage.

    Therapy with either agent is covered only when all specified coverage requirements are met. Requests that do not include a confirmed diagnosis of PH1, required metabolic or genetic testing (as applicable), documentation of specialist prescribing or consultation, adherence to FDA-approved dosing, demonstration of treatment response or required clinical documentation, and applicable kidney function thresholds will not meet medical necessity. Additionally, prior authorization and the documented conditions for initiation or continuation (including limits on initial and reauthorization periods) must be satisfied for coverage to be approved.

    Diagnosis and Billing Codes

    HCPCS / Drug CodesHCPCS
    C9399Unclassified drugs or biologicals
    J0224Unclassified drugs or biologicals
    J3490Unclassified drugs
    Diagnosis CodesICD-10
    E72.530Primary hyperoxaluria, type 1
    E72.538Other specified primary hyperoxaluria
    E72.539Primary hyperoxaluria, unspecified
    E72.541Enteric hyperoxaluria
    E72.548Other secondary hyperoxaluria
    E72.549Secondary hyperoxaluria, unspecified
    inv-07: Urinary oxalate for diagnosis
    Diagnostic 24‑hour urinary oxalate thresholdGreater than 1 mmol/1.73 m2 per day (90 mg/1.73 m2 per day)
    Alternative: spot urinary oxalate:creatinine ratioIncreased urinary oxalate:creatinine ratio relative to normative values for age (use age‑adjusted reference ranges)
    Purpose of measurementMetabolic testing demonstrating increased urinary oxalate excretion supports confirmation of PH1 diagnosis
    inv-08: Normal 24-hour urinary oxalate (BSA-corrected)
    Normal 24‑hour urinary oxalate (BSA‑corrected)≤ 0.514 mmol/24 hr/1.73 m2 (ILLUMINATE‑A reference)
    Context

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; authorizations ≤ 12 months

    Prior authorization is required for Oxlumo (lumasiran) and Rivfloza (nedosiran). Initial authorizations and reauthorizations are each limited to no more than 12 months; requests for services will be evaluated under Ohio Administrative Code when applicable.

    • Applicable HCPCS codes: C9399, J0224, J3490 (listed for billing/authorization reference).
    Step Therapy

    Specialist prescribing; combination therapy disallowed; follow FDA dosing

    Therapy must be prescribed by, or in consultation with, a specialist with PH1 expertise (e.g., geneticist, nephrologist, urologist). Combination use of Oxlumo and Rivfloza is not permitted. Dosing must follow United States FDA–approved labeling.

    • Specialist requirement applies to both initial and continuation requests.
    • Explicit exclusion: patient must not be receiving Oxlumo in combination with Rivfloza (and vice versa).

    Background

    Primary hyperoxaluria type 1 (PH1) is an autosomal recessive metabolic disorder caused by mutations in the AGXT gene that lead to hepatic overproduction of oxalate and progressive kidney damage. The resulting excess oxalate increases urinary and plasma oxalate concentrations, placing patients at risk for nephrolithiasis, nephrocalcinosis, and end-stage renal disease. Lumasiran (Oxlumo) and nedosiran (Rivfloza) are small interfering RNA therapies that target hepatic enzymes in the oxalate production pathway to reduce urinary and/or plasma oxalate levels and are used in PH1 under the coverage conditions described in this policy.

    Definitions

    inv-14: PH1 — definition
    DefinitionPrimary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder caused by mutations in the AGXT gene resulting in deficiency of the hepatic enzyme alanine:glyoxylate aminotransferase (AGT)
    PathophysiologyAGT deficiency leads to hepatic overproduction of glyoxylate→oxalate and increased urinary and plasma oxalate burden
    Clinical implicationLiver transplantation corrects the underlying enzymatic defect; available siRNA therapies target hepatic enzymes to reduce oxalate production
    inv-15: Relatively preserved kidney function
    DefinitionRelatively preserved kidney function: estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
    Policy useRequired threshold for nedosiran (Rivfloza) eligibility for initial and continuation therapy
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyOxlumo (lumasiran) and Rivfloza (nedosiran) — Coverage Criteria (Ohio)
    Policy CodePolicy CSOH2026D0102.F
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with medical records documenting PH1 diagnosis confirmation and, for continuation, evidence of positive clinical response versus pretreatment baseline.
    SourceLink
    On This Page
    Coverage Criteria for Oxlumo and RivflozaDiagnosis and Billing CodesProvider Actions, Prior Authorization, and DocumentationBackgroundDefinitions
    ILLUMINATE‑A primary endpoint: percent reduction in 24‑hour urinary oxalate corrected for BSA; 52% of lumasiran patients achieved this normal value by Month 6
    Use in policyUsed as a benchmark for treatment response when evaluating change from pre‑treatment baseline
  1. Dosing per FDA label for the specific product requested.
  2. Documentation Required

    Required documentation (chart notes, labs, genetic testing, response data)

    Submit medical records documenting diagnosis confirmation and, for continuation requests, evidence of positive clinical response compared with pretreatment baseline.

    • Chart notes confirming diagnosis of PH1 and specialist consultation.
    • Laboratory values such as metabolic testing showing increased urinary oxalate excretion (e.g., >1 mmol/1.73 m2/day or increased urinary oxalate:creatinine ratio) or increased plasma oxalate/glyoxylate concentrations.
    • For nedosiran (Rivfloza) initial requests: genetic testing confirming AGXT mutation.
    • For continuation: documentation of decreased urinary oxalate concentrations, decreased urinary oxalate:creatinine ratio, or decreased plasma oxalate concentrations.
    Denial Risk

    Denial risk if coverage criteria, dosing, specialist involvement, or documentation are unmet

    Requests may be denied if the coverage criteria are not met — including lack of diagnostic confirmation, absence of specialist involvement, failure to follow FDA dosing, or missing required documentation.

    • Denial risk if metabolic testing does not demonstrate increased urinary oxalate excretion or increased plasma oxalate/glyoxylate.
    • Denial risk if no specialist (or consultation) with PH1 expertise is documented.
    • Denial risk if genetic confirmation (AGXT mutation) is required for nedosiran and not provided.
    • Denial risk if combination therapy with the other agent is present.
    Age contextRivfloza indication applies to patients ≥ 2 years of age with relatively preserved kidney function (eGFR ≥ 30 mL/min/1.73 m2)